Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TLPH vs VTVT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TLPH Captures Overall Composite Edge (37.1 SELL vs 39.2 SELL), While VTVT Leads 4–1 on Growth & Valuation Pillars

TLPH Overall Winner 6-Pillar Tally: TLPH 1 – 4 VTVT (1 Tie) Matrix Metrics: TLPH 4 – 5 VTVT

As of Nov 16, 2026, Talphera, Inc. (TLPH) captures the overall head-to-head institutional edge over vTv Therapeutics Inc. (VTVT) on higher Unified Composite conviction (37.1/100 SELL vs. 39.2/100 SELL) after splitting the core matrix 4–5 (led by Valuation Multiples), while VTVT wins 4–1 across the 6-pillar growth and valuation breakdown. TLPH trades at $0.86 (1.0x Forward P/E, -1474700.0% operating margin) versus VTVT at $17.62 (N/M Forward P/E, -29.8% operating margin).

  • Composite vs. Pillar Nuance: While VTVT currently prints a higher short-term Unified Composite Score (39.2/100 SELL vs. TLPH 37.1/100 SELL), TLPH captures the overall institutional head-to-head verdict (4–5 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (-1474700.0% vs. -29.8% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
  • Defensive Composite Rating Caution: Although TLPH compares more favorably head-to-head, both TLPH (37.1/100 SELL) and VTVT (39.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: TLPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile VTVT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 19.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TLPH vs VTVT
TLPH NASDAQ Head-to-Head Winner
Talphera, Inc. Common Stock
Pharmaceutical Preparations
$0.86
-4.98% 1D
Market Cap $53.7M
TTM Revenue $1,000
Forward P/E 1.0x
Beta / 30D Vol 1.11β · 58% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $1.04 · SMA50: $1.10
VTVT NASDAQ
vTv Therapeutics Inc. Class A Common Stock
Pharmaceutical Preparations
$17.62
-10.51% 1D
Market Cap $78.3M
TTM Revenue $37M
Forward P/E N/M
Beta / 30D Vol 1.48β · 53% Vol
Unified Composite Score
39.2 / 100 SELL
Tech 25.0 Fund 44.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.4%), weak momentum, RSI 20
RSI-14: 19.7 · SMA20: $23.70 · SMA50: $27.74

6-Pillar Scorecard Institutional Category Breakdown (TLPH 1 – 4 VTVT)

Columns: Metric · TLPH · VTVT
1. Valuation Multiples TLPH
Forward P/E 1.0x N/M
Trailing P/E 1.0x N/M
PEG Ratio N/M N/M
EV / Revenue N/M 2.1x
2. Growth & Scale VTVT
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1,000 $37M
Market Cap $53.7M $78.3M
3. Profitability & Quality VTVT
Gross Margin N/A 51.5%
Operating Margin -1474700.0% -29.8%
Net Profit Margin 0.0% -20.8%
Return on Equity (ROE) -143.4% -10.9%
4. Balance Sheet & Cash Flow VTVT
Cash Generation (TTM) -$15M EBITDA -$11M EBITDA
Cash Flow Margin N/A -29.8% EBITDA Mgn
Net Cash / Leverage $0.28 Book/Sh · -143.4% ROE $5.61 Book/Sh · -10.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 118.4% (100th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat VTVT
OpEx & R&D Intensity N/A 81.3% of Rev ($30M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TLPH (4) vs VTVT (5)
Institutional Metric TLPH VTVT Criterion Row Edge
Market Capitalization
Scale
$53.7M $78.3M Larger Scale VTVT
Trailing P/E Ratio
Valuation
1.0x N/M Lower Multiple TLPH
Forward P/E Ratio
Valuation
1.0x N/M Lower Multiple TLPH
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
-1474700.0% -29.8% Higher Margin VTVT
Net Profit Margin
Profitability
0.0% -20.8% Higher Margin TLPH
Return on Equity (ROE)
Capital Efficiency
-143.4% -10.9% Higher ROE VTVT
52-Week Range Position
Momentum
20% ($1–$2) 1% ($17–$44) Stronger Trend TLPH
Beta / 30D Volatility
Risk Regime
1.11β · 58% Vol 1.48β · 53% Vol Lower Realized Risk VTVT
Unified Institutional Score
Composite Signal
37.1 / 100 (SELL) 39.2 / 100 (SELL) Higher Composite VTVT
Trailing 12M Revenue (USD)
Operating Scale
$1,000 $37M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 51.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 2.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$15M EBITDA ($0.28 Book/Sh · -143.4% ROE) -$11M EBITDA ($5.61 Book/Sh · -10.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TLPH +13.32 pp
TLPH: -20.29% · VTVT: -33.61%
3M Horizon TLPH +15.18 pp
TLPH: -28.85% · VTVT: -44.03%
6M Horizon TLPH +58.33 pp
TLPH: +7.98% · VTVT: -50.35%
1Y Horizon TLPH +25.64 pp
TLPH: -18.01% · VTVT: -43.65%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TLPH vs VTVT. Trailing 12-month operating profitability (TLPH -1474700.0% vs VTVT -29.8%) and valuation multiples (TLPH 1.0x vs VTVT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

TLPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1,000
Gross MarginN/A
Op. Margin-1474700.0%
ROE / Fwd P/E-143.4% · 1.0x
VTVT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$37M
Gross Margin51.5%
Op. Margin-29.8%
ROE / Fwd P/E-10.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TLPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 118.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VTVT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTVT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TLPH Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $53.7M market capitalization and -1474700.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VTVT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $78.3M market capitalization and -29.8% operating margin.
OpEx & R&D Reinvestment 81.3% of Rev ($30M)
90D Engineering Disclosures 0 Published

Investor FAQ TLPH vs VTVT Key Questions & Quantitative Answers

As of Nov 16, 2026, Talphera, Inc. (TLPH) captures the overall head-to-head institutional edge over vTv Therapeutics Inc. (VTVT) on higher Unified Composite conviction (37.1/100 SELL vs. 39.2/100 SELL) after splitting the core matrix 4–5 (led by Valuation Multiples), while VTVT wins 4–1 across the 6-pillar growth and valuation breakdown. TLPH trades at $0.86 (1.0x Forward P/E, -1474700.0% operating margin) versus VTVT at $17.62 (N/M Forward P/E, -29.8% operating margin). Composite vs. Pillar Nuance: While VTVT currently prints a higher short-term Unified Composite Score (39.2/100 SELL vs. TLPH 37.1/100 SELL), TLPH captures the overall institutional head-to-head verdict (4–5 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (-1474700.0% vs. -29.8% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Defensive Composite Rating Caution: Although TLPH compares more favorably head-to-head, both TLPH (37.1/100 SELL) and VTVT (39.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: TLPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile VTVT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 19.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VTVT leads the Growth & Scale pillar: TLPH posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, -1474700.0% operating margin), compared with VTVT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $37M TTM revenue (51.5% gross margin, -29.8% operating margin). On trailing 12-month operating scale, TLPH generates $1,000 in USD-normalized revenue versus $37M for VTVT. In operating R&D and SG&A reinvestment, TLPH deploys N/A (0 90-day corporate R&D disclosures) versus 81.3% of Rev ($30M) (0 disclosures) for VTVT.

TLPH screens cheaper on headline valuation multiples. TLPH trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas VTVT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.1x EV/Revenue (-29.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TLPH (-143.4% ROE) versus VTVT (-10.9% ROE) capital efficiency.

In options market volatility and institutional positioning, TLPH carries 118.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 58% Vol realized risk). By comparison, VTVT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.48β · 53% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.